rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2021-727-737rsp-3099Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESУратснижающие препараты в лечении подагры: неизвестное об известномUrate-lowering drugs in the treatment of gout: The unknown about the knownhttps://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

Паневин Тарас Сергеевич.

115522, Москва, Каширское шоссе, 34а.

Taras S. Panevin.

115522, Moscow, Kashirskoye Highway, 34A.

tarasel@list.ruhttps://orcid.org/0000-0003-1191-5831ЕлисеевМ. С.EliseevM. S.

115522, Москва, Каширское шоссе, 34а.

Maxim S. Eliseev.

115522, Moscow, Kashirskoye Highway, 34A.

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а; 119991, Москва, ул. Трубецкая, 8, стр. 2.

Evgeny L. Nasonov.

115522, Moscow, Kashirskoye Highway, 34A; 119991, Moscow, Trubetskaya str., 8, building 2.

Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationНаучно-исследовательский институт ревматологии им. В.А. Насоновой; Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation202127122021596727737Copyright © Паневин Т.С., Елисеев М.С., Насонов Е.Л., 20212021Паневин Т.С., Елисеев М.С., Насонов Е.Л.Panevin T.S., Eliseev M.S., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3099

Основным направлением лекарственной терапии подагры и других связанных с гиперурикемией заболеваний является длительное использование лекарственных средств, направленных на коррекцию уровня мочевой кислоты. Однако помимо уратснижающего действия, данные препараты могут обладать и другими благоприятными плейотропными эффектами. В статье будут обсуждены дополнительные эффекты ингибиторов ксантиноксидазы, а также используемых для лечения сопутствующих подагре заболеваний препаратов, обладающих уратснижающим действием.

The main direction of drug therapy for gout and other diseases associated with hyperuricemia is the long-term use of drugs aimed at correcting the level of uric acid. However, in addition to the urate-lowering effect, these drugs may have other beneficial pleiotropic effects. The article will discuss the additional effects of xanthine oxidase inhibitors, as well as drugs used to treat gout-related diseases that have urate-lowering effects.

подаграфибратытиазолидиндионыпиоглитазонлозартанархалофенаталлопуринолфебуксостатбензбромаронgoutfibratesthiazolidinedionespioglitazonelosartanarhalofenateallopurinolfebuxostatbenzbroma-roneReferencesЖелябина ОВ, Елисеев МС. Ингибиторы ксантиноксидазы при асимптоматической гиперурикемии. Современная ревматология. 2019;13(4):137-142. doi: 10.14412/1996-7012-2019-4-137-142Zhelyabina OV, Eliseev MS. Xanthine oxidase inhibitors in asymptomatic hyperuricemia. Modern Rheumatology Journal. 2019;13(4):137-142 (In Russ.). doi: 10.14412/1996-7012-2019-4-137-142Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK. Serum uric acid and the risk of incident and recurrent gout: A systematic review. J Rheumatol. 2017;44(3):388-396. doi: 10.3899/jrheum.160452Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK. Serum uric acid and the risk of incident and recurrent gout: A systematic review. J Rheumatol. 2017;44(3):388-396. doi: 10.3899/jrheum.160452Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 1992;231(1):25-30. doi: 10.1111/j.1365-2796.1992.tb00494.xLaws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 1992;231(1):25-30. doi: 10.1111/j.1365-2796.1992.tb00494.xAbbasian M, Ebrahimi H, Delvarianzadeh M, Norouzi P, Fazli M. Association between serum uric acid (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahroud University of Medical Sciences. Diabetes Metab Syndr. 2016;10(3):132-136. doi: 10.1016/j.dsx.2016.01.003Abbasian M, Ebrahimi H, Delvarianzadeh M, Norouzi P, Fazli M. Association between serum uric acid (SUA) levels and metabolic syndrome (MetS) components in personnel of Shahroud University of Medical Sciences. Diabetes Metab Syndr. 2016;10(3):132-136. doi: 10.1016/j.dsx.2016.01.003Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36(6):1072-1078. doi: 10.1161/01.hyp.36.6.1072Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000;36(6):1072-1078. doi: 10.1161/01.hyp.36.6.1072Кобалава ЖД, Троицкая ЕА. Бессимптомная гиперурикемия и риск развития сердечно-сосудистых и почечных заболеваний. Кардиология. 2020;60(10):113-121. doi: 10.18087/cardio.2020.10.n1153Kobalava ZhD, Troitskaya EA. Asymptomatic hyperuricemia and risk of cardiovascular and renal diseases. Kardiologiia. 2020;60(10):113-121 (In Russ.). doi: 10.18087/cardio.2020.10.n1153Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-38. doi: 10.1136/annrheumdis-2019-215315Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-38. doi: 10.1136/annrheumdis-2019-215315Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al.; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446. doi: 10.1002/acr.21772Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al.; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446. doi: 10.1002/acr.21772Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014;(10):CD006077. doi: 10.1002/14651858.CD006077.pub3Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014;(10):CD006077. doi: 10.1002/14651858.CD006077.pub3Karmouty-Quintana H, Xia Y, Blackburn MR. Adenosine signaling during acute and chronic disease states. J Mol Med (Berl). 2013;91(2):173-181. doi: 10.1007/s00109-013-0997-1Karmouty-Quintana H, Xia Y, Blackburn MR. Adenosine signaling during acute and chronic disease states. J Mol Med (Berl). 2013;91(2):173-181. doi: 10.1007/s00109-013-0997-1Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461(7261):282-286. doi: 10.1038/nature08296Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461(7261):282-286. doi: 10.1038/nature08296Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine. Arterioscler Thromb Vasc Biol. 2012;32(4):856-864. doi: 10.1161/ATVBAHA.111.226845Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine. Arterioscler Thromb Vasc Biol. 2012;32(4):856-864. doi: 10.1161/ATVBAHA.111.226845Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, et al. A2A and A3 adenosine receptor expression in rheumatoid arthritis: Upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther. 2011;13(6):R197. doi: 10.1186/ar3527Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, et al. A2A and A3 adenosine receptor expression in rheumatoid arthritis: Upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther. 2011;13(6):R197. doi: 10.1186/ar3527Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: Adenosine synthesis and function in regulatory T cell biology. J Immunol. 2010;185(4):1993-1998. doi: 10.4049/jimmunol.1000108Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: Adenosine synthesis and function in regulatory T cell biology. J Immunol. 2010;185(4):1993-1998. doi: 10.4049/jimmunol.1000108Herez Ruiz F, Richette P, Stack AG, Karra Gurunath R, Garda de Yebenes MJ, Carmona L. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5(2):e001015. doi: 10.1136/rmdopen-2019-001015Herez Ruiz F, Richette P, Stack AG, Karra Gurunath R, Garda de Yebenes MJ, Carmona L. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5(2):e001015. doi: 10.1136/rmdopen-2019-001015Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584-C596. doi: 10.1152/ajpcell.00600.2006Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584-C596. doi: 10.1152/ajpcell.00600.2006Fabbrini E, Serafini M, Colic Baric I, Hazen SL, Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2014;63(3):976-981. doi: 10.2337/db13-1396Fabbrini E, Serafini M, Colic Baric I, Hazen SL, Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2014;63(3):976-981. doi: 10.2337/db13-1396Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci. 1981;78(11):6858-6862. doi: 10.1073/pnas.78.11.6858Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci. 1981;78(11):6858-6862. doi: 10.1073/pnas.78.11.6858Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease. Movement Disord. 2008;23(12):1653-1657. doi: 10.1002/mds.22139Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease. Movement Disord. 2008;23(12):1653-1657. doi: 10.1002/mds.22139Kang D-H, Puzzle HSU. Dual role as anti-oxidantand pro-oxidant. Electrol Blood Press. 2014;12(1):1. doi: 10.5049/ebp.2014.12.1.1Kang D-H, Puzzle HSU. Dual role as anti-oxidantand pro-oxidant. Electrol Blood Press. 2014;12(1):1. doi: 10.5049/ebp.2014.12.1.1Miric DJ, Kisic BM, Filipovic-Danic S, Grbic R, Dragojevic I, Miric MB, et al. Xanthine oxidase activity in type 2 diabetes melli-tus patients with and without diabetic peripheral neuropathy. J Diabetes Res. 2016;2016:4370490. doi: 10.1155/2016/4370490Miric DJ, Kisic BM, Filipovic-Danic S, Grbic R, Dragojevic I, Miric MB, et al. Xanthine oxidase activity in type 2 diabetes melli-tus patients with and without diabetic peripheral neuropathy. J Diabetes Res. 2016;2016:4370490. doi: 10.1155/2016/4370490Inkster ME, Cotter MA, Cameron NE. Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. Eur J Pharmacol. 2007;561(1_3):63-71. doi: 10.1016/j.ejphar.2006.12.029Inkster ME, Cotter MA, Cameron NE. Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats. Eur J Pharmacol. 2007;561(1_3):63-71. doi: 10.1016/j.ejphar.2006.12.029Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: Release and regulation of pain. Prog Neurobiol. 2003;69(5):313-340. doi: 10.1016/s0301-0082(03)00050-9Sawynok J, Liu XJ. Adenosine in the spinal cord and periphery: Release and regulation of pain. Prog Neurobiol. 2003;69(5):313-340. doi: 10.1016/s0301-0082(03)00050-9Essawy SS, Elbaz AA. Role of adenosine receptors in the anti-nociceptive effects of allopurinol in mice. Eur Rev Med Pharmacol Sci. 2013;17(14):1857-1863.Essawy SS, Elbaz AA. Role of adenosine receptors in the anti-nociceptive effects of allopurinol in mice. Eur Rev Med Pharmacol Sci. 2013;17(14):1857-1863.Connor M. Allopurinol for pain relief: More than just crystal clearance? Br J Pharmacol. 2009;156(1):4-6. doi: 10.1111/j.1476-5381.2008.00065.xConnor M. Allopurinol for pain relief: More than just crystal clearance? Br J Pharmacol. 2009;156(1):4-6. doi: 10.1111/j.1476-5381.2008.00065.xYossif AM, Ibrahim TM, Salem HA, Gamil NM, el-Sayed LM. Effect of high lipid diet and allopurinol on the development of experimentally induced arthritis in rats. Pharmacology. 1995;51(3):160-164. doi: 10.1159/000139330Yossif AM, Ibrahim TM, Salem HA, Gamil NM, el-Sayed LM. Effect of high lipid diet and allopurinol on the development of experimentally induced arthritis in rats. Pharmacology. 1995;51(3):160-164. doi: 10.1159/000139330Schlesinger N, Brunetti L. Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol. Semin Arthritis Rheum. 2020;50(3):444-450. doi: 10.1016/j.semarthrit.2019.11.009Schlesinger N, Brunetti L. Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol. Semin Arthritis Rheum. 2020;50(3):444-450. doi: 10.1016/j.semarthrit.2019.11.009Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, et al. Investigation into the sources of superoxide in human blood vessels: Angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000;101(18):2206-2212. doi: 10.1161/01.cir.101.18.2206Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, et al. Investigation into the sources of superoxide in human blood vessels: Angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000;101(18):2206-2212. doi: 10.1161/01.cir.101.18.2206Yamada I, Fukunari A, Osajima T, Kamezawa M, Mori H, Iwane J. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man. Nucleosides Nucleotides Nucleic Acids. 2004;23(8-9):1123-1125. doi: 10.1081/NCN-200027384Yamada I, Fukunari A, Osajima T, Kamezawa M, Mori H, Iwane J. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man. Nucleosides Nucleotides Nucleic Acids. 2004;23(8-9):1123-1125. doi: 10.1081/NCN-200027384Aldaba-Muruato LR, Moreno MG, Shibayama M, Tsutsumi V, Muriel P. Protective effects of allopurinol against acute liver damage and cirrhosis induced by carbon tetrachloride: Modulation of NF-kB, cytokine production and oxidative stress. Biochim Biophys Acta. 2012;1820(2):65-75. doi: 10.1016/j.bbagen.2011.09.018Aldaba-Muruato LR, Moreno MG, Shibayama M, Tsutsumi V, Muriel P. Protective effects of allopurinol against acute liver damage and cirrhosis induced by carbon tetrachloride: Modulation of NF-kB, cytokine production and oxidative stress. Biochim Biophys Acta. 2012;1820(2):65-75. doi: 10.1016/j.bbagen.2011.09.018Olah T, Regely K, Mandi Y. The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor. Naunyn Schmiedebergs Arch Pharmacol. 1994;350(1):96-99.Olah T, Regely K, Mandi Y. The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor. Naunyn Schmiedebergs Arch Pharmacol. 1994;350(1):96-99.Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol. 2010;40(3):616-619. doi: 10.1002/eji.200940168Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol. 2010;40(3):616-619. doi: 10.1002/eji.200940168Kim SJ, Lee SM. NLRP3 inflammasome activation in d-galactosamine and lipopolysaccharide-induced acute liver failure: Role of heme oxygenase-1. Free Rad Biol Med. 2013;65:997-1004. doi: 10.1016/j.freeradbiomed.2013.08.178Kim SJ, Lee SM. NLRP3 inflammasome activation in d-galactosamine and lipopolysaccharide-induced acute liver failure: Role of heme oxygenase-1. Free Rad Biol Med. 2013;65:997-1004. doi: 10.1016/j.freeradbiomed.2013.08.178Wang W, Wang C, Ding XQ, Pan Y, Gu TT, Wang MX, et al. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol. 2013;169(6):1352-1371. doi: 10.1111/bph.12226Wang W, Wang C, Ding XQ, Pan Y, Gu TT, Wang MX, et al. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol. 2013;169(6):1352-1371. doi: 10.1111/bph.12226Wang W, Xu D, Wang B, Yan S, Wang X, Yin Y, et al. Increased risk of cancer in relation to gout: A review of three prospective cohort studies with 50,358 subjects. Mediators Inflamm. 2015;2015:680853. doi: 10.1155/2015/680853Wang W, Xu D, Wang B, Yan S, Wang X, Yin Y, et al. Increased risk of cancer in relation to gout: A review of three prospective cohort studies with 50,358 subjects. Mediators Inflamm. 2015;2015:680853. doi: 10.1155/2015/680853Chen CJ, Yen JH, Chang SJ. Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol. 2014;43(5):385-390. doi: 10.3109/03009742.2013.878387Chen CJ, Yen JH, Chang SJ. Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol. 2014;43(5):385-390. doi: 10.3109/03009742.2013.878387Kuo CF, Luo SF, See LC, Chou IJ, Fang YF, Yu KH. Increased risk of cancer among gout patients: A nationwide population study. Joint Bone Spine. 2012;79(4):375-378. doi: 10.1016/j.jbspin.2011.09.011Kuo CF, Luo SF, See LC, Chou IJ, Fang YF, Yu KH. Increased risk of cancer among gout patients: A nationwide population study. Joint Bone Spine. 2012;79(4):375-378. doi: 10.1016/j.jbspin.2011.09.011Boffetta P, Nordenvall C, Nyrtn O, Ye W. A prospective study of gout and cancer. Eur J Cancer Prev. 2009;18(2):127-132. doi: 10.1097/CEJ.0b013e328313631aBoffetta P, Nordenvall C, Nyrtn O, Ye W. A prospective study of gout and cancer. Eur J Cancer Prev. 2009;18(2):127-132. doi: 10.1097/CEJ.0b013e328313631aShih HJ, Kao MC, Tsai PS, Fan YC, Huang CJ. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: A population-based study. Prostate Cancer Prostatic Dis. 2017;20(3):328-333. doi: 10.1038/pcan.2017.14Shih HJ, Kao MC, Tsai PS, Fan YC, Huang CJ. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: A population-based study. Prostate Cancer Prostatic Dis. 2017;20(3):328-333. doi: 10.1038/pcan.2017.14Liao KF, Lin CL, Lai SW. Association between allopurinol use and hepatocellular carcinoma in a case-control study in Taiwan. Eur J Hosp Pharm. 2019;26(5):258-261. doi: 10.1136/ejh-pharm-2017-001479Liao KF, Lin CL, Lai SW. Association between allopurinol use and hepatocellular carcinoma in a case-control study in Taiwan. Eur J Hosp Pharm. 2019;26(5):258-261. doi: 10.1136/ejh-pharm-2017-001479Bardin T, Richette P. The role of febuxostat in gout. Curr Opin Rheumatol. 2019;31(2):152-158. doi: 10.1097/BOR.0000000000000573Bardin T, Richette P. The role of febuxostat in gout. Curr Opin Rheumatol. 2019;31(2):152-158. doi: 10.1097/BOR.0000000000000573Inoue MK, Yamamotoya T, Nakatsu Y, Ueda K, Inoue Y, Matsunaga Y, et al. The xanthine oxidase inhibitor febuxostat suppresses the progression of IgA nephropathy, possibly via its anti-inflammatory and anti-fibrotic effects in the gddY mouse model. Int J Mol Sci. 2018;19(12):3967. doi: 10.3390/ijms19123967Inoue MK, Yamamotoya T, Nakatsu Y, Ueda K, Inoue Y, Matsunaga Y, et al. The xanthine oxidase inhibitor febuxostat suppresses the progression of IgA nephropathy, possibly via its anti-inflammatory and anti-fibrotic effects in the gddY mouse model. Int J Mol Sci. 2018;19(12):3967. doi: 10.3390/ijms19123967Bir SC, Kolluru GK, McCarthy P, Shen X, Pardue S, Pattillo CB, et al. Hydrogen sulfide stimulates ischemic vascular remodeling through nitric oxide synthase and nitrite reduction activity regulating hypoxia-inducible factor-1a and vascular endothelial growth factor-dependent angiogenesis. J Am Heart Assoc. 2012;1(5):e004093. doi: 10.1161/JAHA.112.004093Bir SC, Kolluru GK, McCarthy P, Shen X, Pardue S, Pattillo CB, et al. Hydrogen sulfide stimulates ischemic vascular remodeling through nitric oxide synthase and nitrite reduction activity regulating hypoxia-inducible factor-1a and vascular endothelial growth factor-dependent angiogenesis. J Am Heart Assoc. 2012;1(5):e004093. doi: 10.1161/JAHA.112.004093Abdel-Aziz AM, Gamal El-Tahawy NF, Salah Abdel Haleem MA, Mohammed MM, Ali AI, Ibrahim YF. Amelioration of testosterone-induced benign prostatic hyperplasia using febuxostat in rats: The role of VEGF/TGFe and iNOS/COX-2. Eur J Pharmacol. 2020;889:173631. doi: 10.1016/j.ejphar.2020.173631Abdel-Aziz AM, Gamal El-Tahawy NF, Salah Abdel Haleem MA, Mohammed MM, Ali AI, Ibrahim YF. Amelioration of testosterone-induced benign prostatic hyperplasia using febuxostat in rats: The role of VEGF/TGFe and iNOS/COX-2. Eur J Pharmacol. 2020;889:173631. doi: 10.1016/j.ejphar.2020.173631Hao J, Zhang W, Tong R, Huang Z. Febuxostat prevents the cytotoxicity of propofol in brain endothelial cells. ACS Omega. 2021;6(8):5471-5478. doi: 10.1021/acsomega.0c05708Hao J, Zhang W, Tong R, Huang Z. Febuxostat prevents the cytotoxicity of propofol in brain endothelial cells. ACS Omega. 2021;6(8):5471-5478. doi: 10.1021/acsomega.0c05708Zaki SM, Hussein GHA, Khalil HMA, Abd Algaleel WA. Febuxostat ameliorates methotrexate-induced lung damage. Folia Morphol (Warsz). 2021;80(2):392-402. doi: 10.5603/FM.a2020.0075Zaki SM, Hussein GHA, Khalil HMA, Abd Algaleel WA. Febuxostat ameliorates methotrexate-induced lung damage. Folia Morphol (Warsz). 2021;80(2):392-402. doi: 10.5603/FM.a2020.0075Heikal MM, Shaaban AA, Elkashef WF, Ibrahim TM. Effect of febuxostat on biochemical parameters of hyperlipidemia induced by a high-fat diet in rabbits. Can J Physiol Pharmacol. 2019;97(7):611-622. doi: 10.1139/cjpp-2018-0731Heikal MM, Shaaban AA, Elkashef WF, Ibrahim TM. Effect of febuxostat on biochemical parameters of hyperlipidemia induced by a high-fat diet in rabbits. Can J Physiol Pharmacol. 2019;97(7):611-622. doi: 10.1139/cjpp-2018-0731Mizuno Y, Yamamotoya T, Nakatsu Y, Ueda K, Matsunaga Y, Inoue MK, et al. Xanthine oxidase inhibitor febuxostat exerts an anti-inflammatory action and protects against diabetic nephropathy development in KK-Ay obese diabetic mice. Int J Mol Sci. 2019;20(19):4680. doi: 10.3390/ijms20194680Mizuno Y, Yamamotoya T, Nakatsu Y, Ueda K, Matsunaga Y, Inoue MK, et al. Xanthine oxidase inhibitor febuxostat exerts an anti-inflammatory action and protects against diabetic nephropathy development in KK-Ay obese diabetic mice. Int J Mol Sci. 2019;20(19):4680. doi: 10.3390/ijms20194680Nomura J, Kobayashi T, So A, Busso N. Febuxostat, a xanthine oxidoreductase inhibitor, decreases NLRP3-dependent inflammation in macrophages by activating the purine salvage pathway and restoring cellular bioenergetics. Sci Rep. 2019;9(1):17314. doi: 10.1038/s41598-019-53965-xNomura J, Kobayashi T, So A, Busso N. Febuxostat, a xanthine oxidoreductase inhibitor, decreases NLRP3-dependent inflammation in macrophages by activating the purine salvage pathway and restoring cellular bioenergetics. Sci Rep. 2019;9(1):17314. doi: 10.1038/s41598-019-53965-xIbrahim YF, Fadl RR, Ibrahim S, Gayyed MF, Bayoumi A, Refaie M. Protective effect of febuxostat in sepsis-induced liver and kidney injuries after cecal ligation and puncture with the impact of xanthine oxidase, interleukin 1 в, and c-Jun N-terminal kinases. Hum Exp Toxicol. 2020;39(7):906-919. doi: 10.1177/0960327120905957Ibrahim YF, Fadl RR, Ibrahim S, Gayyed MF, Bayoumi A, Refaie M. Protective effect of febuxostat in sepsis-induced liver and kidney injuries after cecal ligation and puncture with the impact of xanthine oxidase, interleukin 1 в, and c-Jun N-terminal kinases. Hum Exp Toxicol. 2020;39(7):906-919. doi: 10.1177/0960327120905957Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, et al. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int. 2014;34(1):101-109. doi: 10.1007/s00296-013-2857-2Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, et al. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int. 2014;34(1):101-109. doi: 10.1007/s00296-013-2857-2Alfaifi MY, Shati AA, Elbehairi SEI, Fahmy UA, Alhakamy NA, Md S. Anti-tumor effect of PEG-coated PLGA nanoparticles of febuxostat on A549 non-small cell lung cancer cells. 3 Biotech. 2020;10(3):133. doi: 10.1007/s13205-020-2077-xAlfaifi MY, Shati AA, Elbehairi SEI, Fahmy UA, Alhakamy NA, Md S. Anti-tumor effect of PEG-coated PLGA nanoparticles of febuxostat on A549 non-small cell lung cancer cells. 3 Biotech. 2020;10(3):133. doi: 10.1007/s13205-020-2077-xNishikawa T, Nagata N, Shimakami T, Shirakura T, Matsui C, Ni Y, et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep. 2020;10(1):815. doi: 10.1038/s41598-020-57784-3Nishikawa T, Nagata N, Shimakami T, Shirakura T, Matsui C, Ni Y, et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep. 2020;10(1):815. doi: 10.1038/s41598-020-57784-3Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther. 2004;26(2):177-190. doi: 10.1016/s0149-2918(04)90017-3Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther. 2004;26(2):177-190. doi: 10.1016/s0149-2918(04)90017-3Furnsinn C, Waldhausl W. Thiazolidinediones: Metabolic actions in vitro. Diabetologia. 2002;45(9):1211-1223. doi: 10.1007/s00125-002-0899-1Furnsinn C, Waldhausl W. Thiazolidinediones: Metabolic actions in vitro. Diabetologia. 2002;45(9):1211-1223. doi: 10.1007/s00125-002-0899-1Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002;25(3):517-523. doi: 10.2337/diacare.25.3.517Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002;25(3):517-523. doi: 10.2337/diacare.25.3.517Iwatani M, Wasada T, Katsumori K. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-dia-betics. Diabetologia. 2000;43(6):814-815. doi: 10.1007/s001250051380Iwatani M, Wasada T, Katsumori K. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-dia-betics. Diabetologia. 2000;43(6):814-815. doi: 10.1007/s001250051380Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: A case study. Am J Med. 2003;114(4):299-306. doi: 10.1016/s0002-9343(02)01529-2Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: A case study. Am J Med. 2003;114(4):299-306. doi: 10.1016/s0002-9343(02)01529-2Kutoh E, Hori T. Effect of pioglitazone on serum uric acid levels in newly diagnosed, drug-naive patients with type 2 diabetes. Endocr Res. 2012;38(3):151-159. doi: 10.3109/07435800.2012.745128Kutoh E, Hori T. Effect of pioglitazone on serum uric acid levels in newly diagnosed, drug-naive patients with type 2 diabetes. Endocr Res. 2012;38(3):151-159. doi: 10.3109/07435800.2012.745128Gotfredsen A, McNair P, Christiansen C, Transbol I. Renal hypouricaemia in insulin treated diabetes mellitus. Clin Chim Acta. 1982;120(3):355-361. doi: 10.1016/0009-8981(82)90376-xGotfredsen A, McNair P, Christiansen C, Transbol I. Renal hypouricaemia in insulin treated diabetes mellitus. Clin Chim Acta. 1982;120(3):355-361. doi: 10.1016/0009-8981(82)90376-xCook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: Relationships in a population study. Postgrad Med J. 1986;62(733):1001-1006. doi: 10.1136/pgmj.62.733.1001Cook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: Relationships in a population study. Postgrad Med J. 1986;62(733):1001-1006. doi: 10.1136/pgmj.62.733.1001Gonzdlez-Ortiz M, Herndndez-Salazar E, Kam-Ramos AM, Martlnez-Abundis E. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;75(1):115-118. doi: 10.1016/j.diabres.2006.05.003Gonzdlez-Ortiz M, Herndndez-Salazar E, Kam-Ramos AM, Martlnez-Abundis E. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;75(1):115-118. doi: 10.1016/j.diabres.2006.05.003Seber S, Ucak S, Basat O, Altuntas Y. The effect of dual PPAR а/Y stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clinical Pract. 2006;71(1):52-58. doi: 10.1016/j.diabres.2005.05.009Seber S, Ucak S, Basat O, Altuntas Y. The effect of dual PPAR а/Y stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clinical Pract. 2006;71(1):52-58. doi: 10.1016/j.diabres.2005.05.009Maalouf NM, Poindexter JR, Adams-Huet B, Moe OW, Sakhaee K. Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone. Kidney Int. 2019;95(5):1262-1268. doi: 10.1016/j.kint.2018.11.024Maalouf NM, Poindexter JR, Adams-Huet B, Moe OW, Sakhaee K. Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone. Kidney Int. 2019;95(5):1262-1268. doi: 10.1016/j.kint.2018.11.024Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65(4):1422-1425. doi: 10.1111/j.1523-1755.2004.00522.xMaalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65(4):1422-1425. doi: 10.1111/j.1523-1755.2004.00522.xTakahashi S, Inokuchi T, Kobayashi T, Ka T, Tsutsumi Z, Moriwaki Y, et al. Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH. Horm Metab Res. 2007;39(7):511-514. doi: 10.1055/s-2007-982517Takahashi S, Inokuchi T, Kobayashi T, Ka T, Tsutsumi Z, Moriwaki Y, et al. Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH. Horm Metab Res. 2007;39(7):511-514. doi: 10.1055/s-2007-982517Gerber P, Lubben G, Heusler S, Dodo A. Effects of pioglitazone on metabolic control and blood pressure: A randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2003;19(6):532-539. doi: 10.1185/030079903125002180Gerber P, Lubben G, Heusler S, Dodo A. Effects of pioglitazone on metabolic control and blood pressure: A randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2003;19(6):532-539. doi: 10.1185/030079903125002180Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005;366(9493):1279-1289. doi: 10.1016/S0140-6736(05)67528-9Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005;366(9493):1279-1289. doi: 10.1016/S0140-6736(05)67528-9DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet. 2006;368(9541):1096-1105. doi: 10.1016/S0140-6736(06)69420-8DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet. 2006;368(9541):1096-1105. doi: 10.1016/S0140-6736(06)69420-8St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25(11):2058-2064. doi: 10.2337/diacare.25.11.2058St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25(11):2058-2064. doi: 10.2337/diacare.25.11.2058Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24(10):2047-2055. doi: 10.1097/01.hjh.0000244955.39491.88Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24(10):2047-2055. doi: 10.1097/01.hjh.0000244955.39491.88Nilsson PM, Hedblad B, Donaldson J, Berglund G. Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance. Blood Press. 2007;16(2):95-100. doi: 10.1080/08037050701396652Nilsson PM, Hedblad B, Donaldson J, Berglund G. Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance. Blood Press. 2007;16(2):95-100. doi: 10.1080/08037050701396652Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23(1):52-57. doi: 10.1161/01.atv.0000044461.01844.c9Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23(1):52-57. doi: 10.1161/01.atv.0000044461.01844.c9Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension. 1994;24(2):170-175. doi: 10.1161/01.hyp.24.2.170Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension. 1994;24(2):170-175. doi: 10.1161/01.hyp.24.2.170Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106(6):679-684. doi: 10.1161/01.cir.0000025403.20953.23Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106(6):679-684. doi: 10.1161/01.cir.0000025403.20953.23Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest. 2002;62(5):337-342. doi: 10.1080/00365510260296483Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest. 2002;62(5):337-342. doi: 10.1080/00365510260296483Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: Decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2007;66(2):282-289. doi: 10.1111/j.1365-2265.2006.02723.xKim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: Decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2007;66(2):282-289. doi: 10.1111/j.1365-2265.2006.02723.xReilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111(7):932-939. doi: 10.1161/01.CIR.0000155620.10387.43Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111(7):932-939. doi: 10.1161/01.CIR.0000155620.10387.43Wang RC, Jiang DM. PPAR-Y agonist pioglitazone affects rat gouty arthritis by regulating cytokines. Genet Mol Res. 2014;13(3):6577-6581. doi: 10.4238/2014.august.28.2Wang RC, Jiang DM. PPAR-Y agonist pioglitazone affects rat gouty arthritis by regulating cytokines. Genet Mol Res. 2014;13(3):6577-6581. doi: 10.4238/2014.august.28.2Niu SW, Chang KT, Lin HY, Kuo IC, Chang YH, Chen YH, et al. Decreased incidence of gout in diabetic patients using pioglitazone. Rheumatology (Oxford). 2018;57(1):92-99. doi: 10.1093/rheumatology/kex363Niu SW, Chang KT, Lin HY, Kuo IC, Chang YH, Chen YH, et al. Decreased incidence of gout in diabetic patients using pioglitazone. Rheumatology (Oxford). 2018;57(1):92-99. doi: 10.1093/rheumatology/kex363Davidson MA, Mattison DR, Azoulay L, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: Past, present and future. Crit Rev Toxicol. 2017;48(1):52-108. doi: 10.1080/10408444.2017.1351420Davidson MA, Mattison DR, Azoulay L, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: Past, present and future. Crit Rev Toxicol. 2017;48(1):52-108. doi: 10.1080/10408444.2017.1351420Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, et al.; IRIS Trial Investigators. Pioglitazone and risk for bone fracture: Safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2017;102(3):914-922. doi: 10.1210/jc.2016-3237Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, et al.; IRIS Trial Investigators. Pioglitazone and risk for bone fracture: Safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2017;102(3):914-922. doi: 10.1210/jc.2016-3237Shahataa MG, Mostafa-Hedeab G, Ali EF, Mahdi EA, Mahmoud FA. Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats. Can J Physiol Pharmacol. 2016;94(8):907-917. doi: 10.1139/cjpp-2016-0090Shahataa MG, Mostafa-Hedeab G, Ali EF, Mahdi EA, Mahmoud FA. Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats. Can J Physiol Pharmacol. 2016;94(8):907-917. doi: 10.1139/cjpp-2016-0090Leahy JL. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. Yearbook of Endocrinology. 2006;2006:73-74. doi: 10.1016/s0084-3741(08)70292-0Leahy JL. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. Yearbook of Endocrinology. 2006;2006:73-74. doi: 10.1016/s0084-3741(08)70292-0Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J. 2004;148(5):747-754. doi: 10.1016/j.ahj.2004.04.037Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J. 2004;148(5):747-754. doi: 10.1016/j.ahj.2004.04.037Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, et al. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008;25(3):639-646. doi: 10.1007/s11095-007-9401-6Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, et al. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008;25(3):639-646. doi: 10.1007/s11095-007-9401-6Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007;320(1):211-217. doi: 10.1124/jpet.106.112755Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007;320(1):211-217. doi: 10.1124/jpet.106.112755Hamada T, Mizuta E, Kondo T, Hirai M, Yamada K, Kato M, et al. Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients. Arzneimittelforschung. 2010;60(2):71-75. doi: 10.1055/s-0031-1296251Hamada T, Mizuta E, Kondo T, Hirai M, Yamada K, Kato M, et al. Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients. Arzneimittelforschung. 2010;60(2):71-75. doi: 10.1055/s-0031-1296251Hamada T, Kuwabara M, Watanabe A, Mizuta E, Ohtahara A, Omodani H, et al. A comparative study on the effectiveness of losartan/hydrochlorothiazide and telmisartan/hydrochlorothia/-ide in patients with hypertension. Clin Exp Hypertens. 2014;36(4):251-257. doi: 10.3109/10641963.2013.810228Hamada T, Kuwabara M, Watanabe A, Mizuta E, Ohtahara A, Omodani H, et al. A comparative study on the effectiveness of losartan/hydrochlorothiazide and telmisartan/hydrochlorothia/-ide in patients with hypertension. Clin Exp Hypertens. 2014;36(4):251-257. doi: 10.3109/10641963.2013.810228Nishida Y, Takahashi Y, Susa N, Kanou N, Nakayama T, Asai S. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: A retrospective observational study. Cardiovasc Diabetol. 2013;12:159. doi: 10.1186/1475-2840-12-159Nishida Y, Takahashi Y, Susa N, Kanou N, Nakayama T, Asai S. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: A retrospective observational study. Cardiovasc Diabetol. 2013;12:159. doi: 10.1186/1475-2840-12-159Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106(25):10338-10342. doi: 10.1073/pnas.0901249106Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106(25):10338-10342. doi: 10.1073/pnas.0901249106Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010;31(2-3):150-161. doi: 10.1002/bdd.699Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010;31(2-3):150-161. doi: 10.1002/bdd.699Deppe S, Ripperger A, Weiss J, Ergun S, Benndorf RA. Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan. Biochem Biophys Res Commun. 2014;443(4):1211-1217. doi: 10.1016/j.bbrc.2013.12.119Deppe S, Ripperger A, Weiss J, Ergun S, Benndorf RA. Impact of genetic variability in the ABCG2 gene on ABCG2 expression, function, and interaction with AT1 receptor antagonist telmisartan. Biochem Biophys Res Commun. 2014;443(4):1211-1217. doi: 10.1016/j.bbrc.2013.12.119Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol. 1980;20(10):560-564. doi: 10.1002/j.1552-4604.1980.tb01670.xDesager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol. 1980;20(10):560-564. doi: 10.1002/j.1552-4604.1980.tb01670.xBastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: Effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism. 1988;37(3):217-220. doi: 10.1016/0026-0495(88)90098-4Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: Effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism. 1988;37(3):217-220. doi: 10.1016/0026-0495(88)90098-4Uetake D, Ohno I, Ichida K, Yamaguchi Y, Saikawa H, Endou H, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med. 2010;49(2):89-94. doi: 10.2169/internalmedicine.49.2597Uetake D, Ohno I, Ichida K, Yamaguchi Y, Saikawa H, Endou H, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med. 2010;49(2):89-94. doi: 10.2169/internalmedicine.49.2597Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57:509-510. doi: 10.1136/ard.57.9.509Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57:509-510. doi: 10.1136/ard.57.9.509Fox IH, John D, DeBruyne S, Dwosh I, Marliss EB. Hyperuricemia and hypertriglyceridemia: Metabolic basis for the association. Metabolism. 1985;34(8):741-746. doi: 10.1016/0026-0495(85)90025-3Fox IH, John D, DeBruyne S, Dwosh I, Marliss EB. Hyperuricemia and hypertriglyceridemia: Metabolic basis for the association. Metabolism. 1985;34(8):741-746. doi: 10.1016/0026-0495(85)90025-3Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuri-caemic agents with fenofibrate andzor losartan on uric acid metabolism. Ann Rheum Dis. 2003;62(6):572-575. doi: 10.1136/ard.62.6.572Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuri-caemic agents with fenofibrate andzor losartan on uric acid metabolism. Ann Rheum Dis. 2003;62(6):572-575. doi: 10.1136/ard.62.6.572Hepburn AL, Kaye SA, Feher MD. Long-term remission from gout associated with fenofibrate therapy. Clin Rheumatol. 2003;22(1):73-76. doi: 10.1007/s10067-002-0658-1Hepburn AL, Kaye SA, Feher MD. Long-term remission from gout associated with fenofibrate therapy. Clin Rheumatol. 2003;22(1):73-76. doi: 10.1007/s10067-002-0658-1Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford). 2003;42(2):321-325. doi: 10.1093/rheumatology/keg103Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford). 2003;42(2):321-325. doi: 10.1093/rheumatology/keg103Hepburn AL, Kaye SA, Feher MD. Fenofibrate: A new treatment for hyperuricaemia and gout? Ann Rheum Dis. 2001;60(10):984-986. doi: 10.1136/ard.60.10.984aHepburn AL, Kaye SA, Feher MD. Fenofibrate: A new treatment for hyperuricaemia and gout? Ann Rheum Dis. 2001;60(10):984-986. doi: 10.1136/ard.60.10.984ade la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther. 1999;66(2):166-172. doi: 10.1053/cp.1999.v66.99709de la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther. 1999;66(2):166-172. doi: 10.1053/cp.1999.v66.99709Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L, et al.; FIELD investigators. Effect of fenofibrate on uric acid and gout in type 2 diabetes: A post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol. 2018;6(4):310-318. doi: 10.1016/S2213-8587(18)30029-9Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L, et al.; FIELD investigators. Effect of fenofibrate on uric acid and gout in type 2 diabetes: A post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol. 2018;6(4):310-318. doi: 10.1016/S2213-8587(18)30029-9Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol. 2001;28(10):2294-2297Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol. 2001;28(10):2294-2297Yoon M. The role of PPARalpha in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res. 2009;60(3):151-159. doi: 10.1016/j.phrs.2009.02.004Yoon M. The role of PPARalpha in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res. 2009;60(3):151-159. doi: 10.1016/j.phrs.2009.02.004Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun. 2006;341(4):973-978. doi: 10.1016/j.bbrc.2006.01.052Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun. 2006;341(4):973-978. doi: 10.1016/j.bbrc.2006.01.052Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: Energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002. doi: 10.1621/nrs.08002Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: Energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002. doi: 10.1621/nrs.08002Villarroel M, Garcia-Ramirez M, Corraliza L, Herndndez C, Sim6 R. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1e by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia. 2011;54(6):1543-1553. doi: 10.1007/s00125-011-2089-5Villarroel M, Garcia-Ramirez M, Corraliza L, Herndndez C, Sim6 R. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1e by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia. 2011;54(6):1543-1553. doi: 10.1007/s00125-011-2089-5Deng Y, Han X, Yao Z, Sun Y, Yu J, Cai J, et al. PPARa agonist stimulated angiogenesis by improving endothelial precursor cell function via a NLRP3 inflammasome pathway. Cell Physiol Biochem. 2017;42(6):2255-2266. doi: 10.1159/000479999Deng Y, Han X, Yao Z, Sun Y, Yu J, Cai J, et al. PPARa agonist stimulated angiogenesis by improving endothelial precursor cell function via a NLRP3 inflammasome pathway. Cell Physiol Biochem. 2017;42(6):2255-2266. doi: 10.1159/000479999Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447-452. doi: 10.1038/nature742Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447-452. doi: 10.1038/nature742Butler EG, Ichida T, Maruyama H, Schulte-Hermann R, Williams GM. Toxicological studies on a benzofurane derivative. II. Demonstration of peroxisome proliferation in rat liver. Toxicol Appl Pharmacol. 1990;106(3):500-508. doi: 10.1016/0041-008x(90)90344-tButler EG, Ichida T, Maruyama H, Schulte-Hermann R, Williams GM. Toxicological studies on a benzofurane derivative. II. Demonstration of peroxisome proliferation in rat liver. Toxicol Appl Pharmacol. 1990;106(3):500-508. doi: 10.1016/0041-008x(90)90344-tKunishima C, Inoue I, Oikawa T, Nakajima H, Komoda T, Katayama S. Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. PPAR Res. 2007;2007:36092. doi: 10.1155/2007/36092Kunishima C, Inoue I, Oikawa T, Nakajima H, Komoda T, Katayama S. Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. PPAR Res. 2007;2007:36092. doi: 10.1155/2007/36092Abdel-Razek EA, Abo-Youssef AM, Azouz AA. Benzbromarone mitigates cisplatin nephrotoxicity involving enhanced peroxisome proliferator-activated receptor-alpha (PPAR-a) expression. Life Sci. 2020;243:117272. doi: 10.1016/j.lfs.2020.117272Abdel-Razek EA, Abo-Youssef AM, Azouz AA. Benzbromarone mitigates cisplatin nephrotoxicity involving enhanced peroxisome proliferator-activated receptor-alpha (PPAR-a) expression. Life Sci. 2020;243:117272. doi: 10.1016/j.lfs.2020.117272Niu SW, Chang KT, Ta A, Chang YH, Kuo IC, Hung CC, et al. Decreased incidence of diabetes in patients with gout using benzbromarone. Rheumatology (Oxford). 2018;57(9):1574-1582. doi: 10.1093/rheumatology/key138Niu SW, Chang KT, Ta A, Chang YH, Kuo IC, Hung CC, et al. Decreased incidence of diabetes in patients with gout using benzbromarone. Rheumatology (Oxford). 2018;57(9):1574-1582. doi: 10.1093/rheumatology/key138Neogi T, Choi HK. Editorial: Pursuit of a dual-benefit antigout drug: A first look at arhalofenate. Arthritis Rheumatol. 2016;68(8):1793-1796. doi: 10.1002/art.39687Neogi T, Choi HK. Editorial: Pursuit of a dual-benefit antigout drug: A first look at arhalofenate. Arthritis Rheumatol. 2016;68(8):1793-1796. doi: 10.1002/art.39687Gregoire FM, Zhang F, Clarke HJ, Gustafson TA, Sears DD, Favelyukis S, et al. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009;23(7):975-988. doi: 10.1210/me.2008-0473Gregoire FM, Zhang F, Clarke HJ, Gustafson TA, Sears DD, Favelyukis S, et al. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009;23(7):975-988. doi: 10.1210/me.2008-0473Lavan BE, McWherter C, Choi YJ. FRI0403 Arhalofenate, a novel uricosuric agent, is an inhibitor of human uric acid transporters. Ann Rheum Dis. 2013;71:450-451. doi: 10.1136/annrheumdis-2012-eular.2860Lavan BE, McWherter C, Choi YJ. FRI0403 Arhalofenate, a novel uricosuric agent, is an inhibitor of human uric acid transporters. Ann Rheum Dis. 2013;71:450-451. doi: 10.1136/annrheumdis-2012-eular.2860Bardin T, Richette P. Novel uricosurics. Rheumatology (Oxford). 2018;57(Suppl 1):i42-i46. doi: 10.1093/rheumatology/kex433Bardin T, Richette P. Novel uricosurics. Rheumatology (Oxford). 2018;57(Suppl 1):i42-i46. doi: 10.1093/rheumatology/kex433Choi YJ, Larroca V, Lucman A, Vicena V, Abarca N, Rantz T, et al. Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties [abstract]. Arthritis Rheum. 2012;64(Suppl):S697.Choi YJ, Larroca V, Lucman A, Vicena V, Abarca N, Rantz T, et al. Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties [abstract]. Arthritis Rheum. 2012;64(Suppl):S697.Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, et al.; Arhalofenate Flare Study Investigators. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. 2016;68(8):2027-2034. doi: 10.1002/art.39684Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, et al.; Arhalofenate Flare Study Investigators. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. 2016;68(8):2027-2034. doi: 10.1002/art.39684Steinberg AS, Vince BD, Choi YJ, Martin RL, McWherter CA, Boudes PF. The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout. J Rheumatol. 2017;44(3):374-379. doi: 10.3899/jrheumSteinberg AS, Vince BD, Choi YJ, Martin RL, McWherter CA, Boudes PF. The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout. J Rheumatol. 2017;44(3):374-379. doi: 10.3899/jrheumMcWherter C, Choi YJ, Serrano RL, Mahata SK, Terkeltaub R, Liu-Bryan R. Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling. Arthritis Res Ther. 2018;20(1):204. doi: 10.1186/s13075-018-1699-4McWherter C, Choi YJ, Serrano RL, Mahata SK, Terkeltaub R, Liu-Bryan R. Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling. Arthritis Res Ther. 2018;20(1):204. doi: 10.1186/s13075-018-1699-4

The authors declare that there are no conflicts of interest present.